Immuneed is developing a novel, long synthetic peptide vaccine conjugate for cancer treatment. Our strategy is based on the delivery of our vaccine in an antigen-antibody immune complex formula. The unique and ultimate goal is to ensure that the antigen is delivered to the same antigen-presenting cells that are also activated by the immune complex.
The vaccine candidate is based on a conjugate in which a linear B cell epitope derived from tetanus toxoid (patented) is coupled to multiple tumor-derived T cell epitopes. In a clinical setting this will aid efficient antigen delivery to dendritic cells (DC) as well as boost their maturation. The advantage is improved T cell activation and ultimately enhanced anti-tumor response. The T cells can target advanced diseases without systemic toxicity. Altogether, linking a B cell epitope to any tumor-associated antigen of interest makes this strategy unique.
Importantly, we are applying our unique whole-blood loop assay to characterize the vaccine before clinical trial.
Please contact us if you are interested in our unique technique. We may be able to provide you with a strategy that facilitates antigen delivery as well as DC activation.